BiotechTube

Desidustat Oral Tablet + Epoetin Alfa

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Kidney Disease Stage 5 on Dialysis

Conditions

Chronic Kidney Disease Stage 5 on Dialysis

Trial Timeline

Jan 4, 2020 → Sep 2, 2021

NCT ID
NCT04215120

About Desidustat Oral Tablet + Epoetin Alfa

Desidustat Oral Tablet + Epoetin Alfa is a phase 3 stage product being developed by Zydus Lifesciences for Chronic Kidney Disease Stage 5 on Dialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT04215120. Target conditions include Chronic Kidney Disease Stage 5 on Dialysis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04215120Phase 3Completed

Competing Products

20 competing products in Chronic Kidney Disease Stage 5 on Dialysis

See all competitors
ProductCompanyStageHype Score
macitentan 10 mgBML, Inc.Phase 3
76
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
47
TERN-701Terns PharmaceuticalsPhase 1/2
38
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
28
LY3556050 + PlaceboEli LillyPhase 2
52
THB001Third Harmonic BioPhase 1
25
BriquilimabJasper TherapeuticsPhase 1/2
33
BriquilimabJasper TherapeuticsPhase 1/2
33
BriquilimabJasper TherapeuticsPhase 2
44
Empagliflozin + Matching placeboEli LillyPhase 3
77
LY3461767 + PlaceboEli LillyPhase 1
33
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
77
LY3526318 + PlaceboEli LillyPhase 2
52
PirtobrutinibEli LillyPhase 2
52
Ibrutinib + LY3214996Eli LillyPhase 1
33
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
52
LYR-210Lyra TherapeuticsPhase 2
44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)Lyra TherapeuticsPhase 2
44
480 Mometasone Furoate Sinus Drug DepotLyra TherapeuticsPhase 1
25
LYR-210 + Sham procedure controlLyra TherapeuticsPhase 3
69

Other Products from Zydus Lifesciences

SaroglitazarApproved
85
DesidustatApproved
85
Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel + DUAC® Gel + PlaceboPhase 3
77
Pertuzumab (ZRC-3277) + Pertuzumab (Perjeta®)Phase 3
77
Desidustat Oral Tablet + Darbepoetin AlfaPhase 3
77